Long-term outcomes of tyrosine kinase inhibitor discontinuation in patients with metastatic renal cell carcinoma

2015 ◽  
Vol 77 (2) ◽  
pp. 339-347 ◽  
Author(s):  
Dong-Hoe Koo ◽  
Inkeun Park ◽  
Jin-Hee Ahn ◽  
Dae-Ho Lee ◽  
Dalsan You ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Kinase Inhibitor ◽  
Long Term Outcomes ◽  
Tyrosine Kinase Inhibitor Discontinuation

Metastatic renal cell carcinoma: how to make the best sequencing decision after withdrawal for intolerance to a tyrosine kinase inhibitor

2013 ◽  
Vol 9 (6) ◽  
pp. 831-843 ◽  
Author(s):  
Roberto Sabbatini ◽  
Cinizia Ortega ◽  
Giuseppe Procopio ◽  
Cristina Masini ◽  
Enzo Galligioni ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Kinase Inhibitor

scholarly journals Prediction of early progression of metastatic renal cell carcinoma treated with first-line tyrosine kinase inhibitor

2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Jun Teishima ◽  
Daiki Murata ◽  
Shogo Inoue ◽  
Tetsutaro Hayashi ◽  
Koji Mita ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Kinase Inhibitor ◽  
First Line ◽  
Early Progression

scholarly journals Metastatic renal cell carcinoma, the possibility of targeted therapy. Case.

2021 ◽  
pp. 138-144
Author(s):  
K. V. Menshikov ◽  
A. A. Izmailov ◽  
A. V. Sultanbaev ◽  
Sh. I. Musin ◽  
V. S. Chalov ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Growth Factor ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Kinase Inhibitor ◽  
Growth Factor Receptor ◽  
Malignant Neoplasms

Malignant neoplasms of the kidney are quite an urgent problem. In the Russian Federation in 2019, 20758 patients with a newly diagnosed renal cell carcinoma were registered; it should be noted that at the end of 2019, 177 755 patients with this diagnosis were registered. Clear cell carcinoma of the kidney is the most common (75–80%) and most studied subtype of renal cell carcinoma. Because renal cell carcinoma is resistant to chemotherapy, interleukin-2 or interferon alpha has previously been widely used as the first line of treatment for metastatic disease. Sunitinib is an oral tyrosine kinase inhibitor that includes the vascular endothelial growth factor receptor (VEGFR) and the platelet growth factor receptor (PDGFR). Two phase II studies of sunitinib as an anti-angiogenic agent have shown clinical efficacy in patients who progressed on cytokine therapy. Currently, in connection with the development of immuno-oncological drugs, tyrosine kinase inhibitors are fading into the background. It should also be noted that immuno-oncological drugs have their own spectrum of contraindications and immune-mediated toxicity. A clinical case of treatment of a patient with metastatic renal cell carcinoma in the group with a favorable prognosis for IMDC and contraindications to immunotherapy is presented. A history of autoimmune thyroiditis, which was previously treated with levothyroxine sodium, contraindicated treatment with checkpoint inhibitors. The  patient started therapy with the  tyrosine kinase inhibitor sunitinib. Sunitinib therapy made it possible to achieve disease control for  more than 4  years with satisfactory tolerance. The noted adverse events were stopped during therapy and did not lead to a reduction in doses of sunitinib and its cancellation. 

Sign in / Sign up

Export Citation Format

Share Document